World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
55
Citations
15845
World Ranking
3778
National Ranking
154

Sean Emery publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Sean Emery sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 217 publications — 41st percentile

41% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Sean Emery D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Sean Emery sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 55 D-Index — 24th percentile

24% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Sean Emery is affiliated with the University of New South Wales in Australia. Their primary research field is Medicine, with a focus on several subfields including Infectious Diseases, Epidemiology, Virology, Emergency Medicine, and Cardiology and Cardiovascular Medicine. The majority of their work concentrates on topics related to HIV/AIDS drug development and treatment, Pneumocystis jirovecii pneumonia detection and treatment, HIV/AIDS research and interventions, and various aspects of fungal infections and antifungal resistance.

The scientist has contributed to notable recent research papers, including:

  • "Immunizations with diverse sarbecovirus receptor-binding domains elicit SARS-CoV-2 neutralizing antibodies against a conserved site of vulnerability" (2021, Immunity)
  • "Long-Term Benefits from Early Antiretroviral Therapy Initiation in HIV Infection" (2023, NEJM Evidence)
  • "Epidemiology of candidemia in NICE area, France: A five-year study of antifungal susceptibility and mortality" (2021, Journal de Mycologie Médicale)
  • "Dolutegravir plus boosted darunavir versus recommended standard-of-care antiretroviral regimens in people with HIV-1 for whom recommended first-line non-nucleoside reverse transcriptase inhibitor therapy has failed (D2EFT): an open-label, randomised, phase 3b/4 trial" (2024, The Lancet HIV)
  • "2021 update to HIV-TRePS: a highly flexible and accurate system for the prediction of treatment response from incomplete baseline information in different healthcare settings" (2021, Journal of Antimicrobial Chemotherapy)

Frequent coauthors collaborating on research with Sean Emery include Anthony D. Kelleher, Nnakelu Eriobu, Anchalee Avihingsanon, Marcelo Losso, and Sounkalo Dao.

The scientist's research has been published in a range of venues, with multiple works appearing in journals such as Immunity, The Lancet HIV, NEJM Evidence, Journal de Mycologie Médicale, and Journal of Antimicrobial Chemotherapy.

Sean Emery's work spans diverse aspects of infectious diseases, particularly focusing on HIV/AIDS and fungal infections. Their research addresses the development and evaluation of antiretroviral therapies, the epidemiology and treatment of fungal infections like candidemia and Pneumocystis jirovecii pneumonia, and the prediction of treatment response in HIV care. This body of work contributes to multiple areas within medicine and infectious disease research.

Best Publications

  • Circulating microRNAs in sera correlate with soluble biomarkers of immune activation but do not predict mortality in ART treated individuals with HIV-1 infection : a case control study

    Daniel D. Murray;Kazuo Suzuki;Matthew Law;Jonel Trebicka

  • CD4+ count-guided interruption of antiretroviral treatment.

    Wafaa El-Sadr;Wafaa El-Sadr;Jens D Lundgren;James Neaton;Fred Gordin

  • Initiation of antiretroviral therapy in early asymptomatic HIV infection

    Sean Emery;Shweta Sharma;Gerd Fätkenheuer;Josep M. Llibre

  • Plasma Levels of Soluble CD14 Independently Predict Mortality in HIV Infection

    Netanya Sandler;Handan Wand;Annelys Roque;Matthew G Law

  • Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study

    Sean Emery;Jacqueline A. Neuhaus;Andrew N. Phillips;Abdel Babiker

  • Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study

    Benjamin R Bavinton;Angie N Pinto;Nittaya Phanuphak;Beatriz Grinsztejn

  • Interleukin-2 therapy in patients with HIV infection.

    D. Abrams;Y. Lévy;M. H. Losso;A. Babiker

  • Prevalence of Metabolic Syndrome in HIV-Infected Patients Receiving Highly Active Antiretroviral Therapy Using International Diabetes Foundation and Adult Treatment Panel III Criteria: Associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and hypoadiponectinemia

    Katherine Samaras;Handan Wand;Matthew Law;Sean Emery

  • Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study.

    Allison Martin;Don E Smith;Andrew Carr;Clare Ringland

  • Simplification of Antiretroviral Therapy with Tenofovir-Emtricitabine or Abacavir-Lamivudine: A Randomized, 96-Week Trial

    Allison Martin;Mark Bloch;Janaki Amin;David Baker

  • No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial

    Andrew Carr;Cassy Workman;Dianne Carey;Gary Rogers

  • HIV lipodystrophy: prevalence, severity and correlates of risk in Australia.

    J Miller;A Carr;S Emery;M Law

  • Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: Role of CD4+ cell counts and HIV RNA levels during follow-up

    Jens D. Lundgren;Abdel Babiker;Wafaa El-Sadr;Sean Emery

  • Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection.

    Handan Wand;Alexandra Calmy;Dianne L Carey;Katherine Samaras

  • Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase

    John M Murray;Sean Emery;Anthony D Kelleher;Matthew Law

  • Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study.

    Mark A Boyd;N Kumarasamy;Cecilia L Moore

  • In Vivo, Nucleoside Reverse-Transcriptase Inhibitors Alter Expression of Both Mitochondrial and Lipid Metabolism Genes in the Absence of Depletion of Mitochondrial DNA

    Patrick W. G. Mallon;Patrick Unemori;Rebecca Sedwell;Adrienne Morey

  • High Levels of Human Antigen-Specific CD4+ T Cells in Peripheral Blood Revealed by Stimulated Coexpression of CD25 and CD134 (OX40)

    John J. Zaunders;Mee Ling Munier;Nabila Seddiki;Sarah Pett

  • Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial.

    Rebekah L. Puls;Janaki Amin;Marcelo Losso;Praphan Phanuphak

  • Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: A randomized trial

    W M El-Sadr;B Grund;J Neuhaus

  • Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study

    Abdel G Babiker;Sean Emery;Gerd Fätkenheuer;Fred M Gordin

  • Pooled Analysis of 3 Randomized, Controlled Trials of Interleukin-2 Therapy in Adult Human Immunodeficiency Virus Type 1 Disease

    S. Emery;W. B. Capra;D. A. Cooper;R. T. Mitsuyasu

  • Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study

    Dianne Carey;Rebekah Puls;Janaki Amin

  • Does Choice of Combination Antiretroviral Therapy (cART) Alter Changes in Cerebral Function Testing after 48 Weeks in Treatment-Naive, HIV-1–Infected Individuals Commencing cART? A Randomized, Controlled Study

    Alan Winston;Chris Duncombe;Patrick C. K. Li;John M. Gill

  • Minor changes in calculated creatinine clearance and anion‐gap are associated with tenofovir disoproxil fumarate‐containing highly active antiretroviral therapy

    A Winston;J Amin;Pwg Mallon;Pwg Mallon;D Marriott

  • Outpatient Continuous Intravenous Interleukin-2 or Subcutaneous, Polyethylene Glycol—Modified Interleukin-2 in Human Immunodeficiency Virus—Infected Patients: A Randomized, Controlled, Multicenter Study

    Andrew Carr;Sean Emery;Andrew Lloyd;Jennifer Hoy

Frequent Co-Authors

David A. Cooper
David A. Cooper University of New South Wales
Anthony D. Kelleher
Anthony D. Kelleher University of New South Wales
Janaki Amin
Janaki Amin Macquarie University
Andrew Carr
Andrew Carr University of Oxford
Matthew Law
Matthew Law University of New South Wales
James D. Neaton
James D. Neaton University of Minnesota
Jens D. Lundgren
Jens D. Lundgren Rigshospitalet
Jennifer F Hoy
Jennifer F Hoy Monash University
Kiat Ruxrungtham
Kiat Ruxrungtham Chulalongkorn University
Stephen J. Kent
Stephen J. Kent University of Melbourne

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying immunology opens doors to diverse healthcare careers, many of which can be supported by complementary online degree programs. For those interested in advancing clinical skills quickly, accelerated NP programs online offer a fast track to becoming nurse practitioners specializing in immunology-related fields.

Individuals without a nursing background can also explore online nursing programs for non nurses designed to build foundational knowledge and clinical skills from the ground up. These programs often lead to licensure and can be stepping stones toward more advanced immunology careers.

For a quicker entry into nursing, many consider accelerated BSN programs for non nurses, which provide an efficient pathway from a non-nursing background to becoming a registered nurse. This can be critical for those aiming to work in immunology labs or patient care in related specialties.

Additionally, accredited LPN programs easy to get into offer accessible routes for entry-level nursing roles. These positions are valuable for gaining practical experience in immunology-focused healthcare settings and can serve as a foundation for future academic and career advancements.

Best Scientists Citing Sean Emery

Trending Scientists

Recently Published Articles